用 AI 重新定義 IVF 成功率 Formosa Medical Group 是一間專注於 AI 輔助生殖醫學的醫療科技公司，透過深度學習與大數據提升 IVF 成功率，協助診所與醫院在同樣資源下，創造更好的臨床結果與營運表現。 AI-Powered IVF Outcomes Formosa Medical Group is an AI-driven fertility technology company that leverages deep learning and data to improve IVF outcomes, helping clinics achieve better results and economics with existing resources.
高成長市場 / High-growth vertical

聚焦快速成長的 IVF 與女性健康賽道，尤其鎖定亞太區龐大且持續上升的不孕症與高齡生育需求。

Focused on the rapidly expanding IVF and women’s health market, with strong structural demand in Asia driven by infertility and delayed childbirth.

深度技術護城河 / Deep tech moat

自研 3D 胚胎影像深度學習模型與生物標記整合演算法，搭配專利佈局與臨床合作，形成技術與資料雙重優勢。

Proprietary 3D embryo imaging models and biomarker-integrated algorithms, reinforced by IP strategy and clinical collaborations.

可擴展商業模式 / Scalable business model

結合 On-premise 授權與 Cloud / SaaS，面向大型醫院與中小型診所，具備高毛利與可擴張性。

Hybrid on-premise and cloud/SaaS offerings targeting both large hospital groups and mid-sized clinics, with attractive software margins.

清晰成長藍圖 / Clear growth roadmap

已規劃 2025-2030 之監管註冊、國家擴展與潛在資本市場路徑，利於中長期退出與回報。

2025-2030 regulatory, geographic, and commercialization milestones designed to support mid- to long-term value creation and exit options.

我們是 Formosa Medical Group / We Are Formosa Medical Group

Formosa Medical Group 成立於香港，專注於 AI 輔助生殖醫學與 IVF 臨床決策支援技術。
團隊結合生殖醫學專家、AI 科學家與醫療產業經營者，從實際臨床工作流程出發，設計可落地、可擴展的數據與軟體解決方案，目標成為亞洲 IVF 領域的關鍵技術基礎設施供應商。

Formosa Medical Group is a Hong Kong–based company focused on AI-enabled reproductive medicine and IVF decision support.
By combining reproductive medicine expertise, AI research, and healthcare business experience, Formosa aims to build the infrastructure layer for IVF in Asia, delivering real-world, scalable tools to clinics and hospitals.

IVF 需要更「可預測」與「可規模化」 / IVF Needs to Be More Predictable and Scalable

目前多數 IVF 決策仍高度依賴醫師個人經驗，胚胎評估主觀性強，不同醫師、不同中心之間的成功率差異顯著。
在快速成長的市場中，診所同時面臨：人力不足、病人期望提高、成本與品質壓力，急需更客觀、可標準化的工具來支援臨床決策與病人溝通。
IVF outcomes still vary widely across physicians and centers, as embryo grading and treatment planning remain largely experience-based.
Clinics face staffing constraints, rising patient expectations, and economic pressure, and need objective, standardized tools to support decision-making and patient communication.

從胚胎影像到決策支援的 AI 引擎 / An AI Engine from Embryo Imaging to Clinical Decisions

Formosa 建立一套由影像與數據驅動的 IVF AI 平台：
透過 3D 胚胎影像深度學習模型，提供客觀的胚胎品質評分，提升評估一致性。
結合病人年齡、荷爾蒙指標與治療方案，預測成功率與療程風險，協助醫師設計個人化策略。
將上述模型包裝為臨床友善的軟體工具，嵌入既有 IVF 流程與系統中，而非要求醫師「為了 AI 改變流程」。
Formosa is building an IVF AI platform that:
Uses 3D embryo imaging models to deliver objective, standardized embryo quality scores.
Integrates patient profiles and treatment protocols to generate personalized outcome predictions and risk insights.
Delivers these capabilities through clinic-friendly software that fits into existing IVF workflows, rather than forcing clinics to redesign their processes around AI.

團隊與顧問 / Team & Advisors

Formosa 的核心團隊橫跨 AI、醫療與商業三個領域：/The core team brings together expertise in AI, reproductive medicine, and healthcare business:
包含深度學習工程師、資料科學家與產品經理，專注於將演算法轉化為穩定、可商用的解決方案。
Deep learning engineers, data scientists, and product managers focused on building robust, deployable software tools.
技術與產品團隊/Technology & Product
由多位具有豐富 IVF 實務經驗的生殖醫學專家組成，指導產品設計與臨床驗證。
Senior IVF clinicians who co-design the products and oversee clinical validation.
醫學顧問/Medical Advisors
具 AI 醫療影像與生殖醫學研究背景，長期專注於醫療 AI 技術落地與專利策略。
Background in medical imaging AI and reproductive medicine, with experience in leading AI commercialization and IP strategy.
創辦人／CEO

IVF AI 產品線概覽 / IVF AI Product Suite

Formosa 目前聚焦於兩大產品線，環繞 IVF 臨床流程設計：
1. AI 胚胎評分與選擇系統
2. IVF 臨床決策支援與預測工具
未來將在同一數據與模型基礎上，延伸至更多婦產科與生殖醫學應用。

Formosa is building two core IVF product lines:
1. AI-based Embryo Scoring & Selection
2. IVF Clinical Decision Support & Outcome Prediction
These products share a common data and model foundation, enabling future expansion into broader fertility and women’s health applications.

AI 胚胎評分與選擇系統 / AI-based Embryo Scoring & Selection

利用 3D 胚胎影像與深度學習演算法，自動輸出胚胎品質評分與風險指標，降低評估主觀性。
支援與實驗室既有影像設備與工作流程整合，減少導入阻力。
目標是協助診所提升累積活產率，並減少不必要的週期與成本。
Uses 3D embryo imaging and deep learning algorithms to generate standardized embryo quality scores and risk indicators.
Integrates with existing lab imaging setups and workflows to minimize disruption.
Aims to improve cumulative live birth rates while reducing unnecessary cycles and costs.

IVF 臨床決策支援與預測工具 /IVF Clinical Decision Support & Outcome Prediction

結合病人年齡、荷爾蒙數值（如 AMH 等）、既往療程資料與方案設計，提供個人化成功率預估。
協助醫師在療程設計、移植策略與病人諮詢時，有清楚的數據佐證。
提供視覺化報表，讓病人更容易理解不同方案的風險與預期結果。
Integrates patient age, hormone profiles, prior cycles, and protocol choices to provide personalized success-rate predictions.
Supports physicians in designing treatment strategies and communicating options with patients using transparent, data-driven insights.
Delivers visual reports that help patients understand trade-offs and expected outcomes.

市場機會 / Market Opportunity

全球 IVF 週期與支出在未來十年預計持續成長，亞洲因高齡生育與生活型態改變，成長速度尤為明顯。
然而，臨床流程與決策工具仍然相對傳統，Formosa 所提供的 AI 解決方案，正好站在「高成長需求」與「技術升級缺口」的交會點。
Global IVF cycles and spending are expected to grow strongly over the coming decade, with Asia showing particularly robust demand due to demographic and lifestyle shifts.
Yet clinical workflows and decision tools remain largely traditional, positioning Formosa at the intersection of strong market demand and technology upgrade needs.

商業模式與擴張策略 / Business Model & Scaling

收費模式：結合 On-premise 年度授權、Cloud / SaaS 訂閱與技術授權／收入分成，兼顧大型醫院與中小型診所需求。
擴張策略：自核心市場起步，優先布局監管相對成熟且 IVF 需求強勁的地區，逐步擴展合作夥伴與產品線。
Revenue model: A mix of on-premise licensing, cloud/SaaS subscriptions, and technology partnerships with revenue sharing, addressing both large hospital groups and mid-sized clinics.
Scaling strategy: Start from core markets with strong IVF demand and clearer regulatory pathways, then expand through partnerships and product extension.

布局在結構性成長的 IVF 與女性健康市場。
Positioned in a structurally growing IVF and women’s health market.

擁有專有演算法、專利與臨床連結所組成的技術護城河。
Defensible technology moat combining proprietary algorithms, IP, and clinical integration.

以軟體與數據為核心，具備高毛利與可複製的商業模式。
Software- and data-centric business model with attractive margins and scalability.

已規劃 2025-2030 年的監管與商業里程碑，為潛在退出提供清晰故事線。
Defined 2025-2030 regulatory and commercialization milestones that support a clear exit narrative.